Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results